CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...